Skip to content

Trial Summary

This trial (MONARCC) seeks to determine what the best initial treatment is for a patient population with metastatic colorectal cancer that cannot withstand the expected side effects of the commonly used combination chemotherapy regimens.

Acronym:

MONARCC

ACTRN/NCT /ethics:

ACTRN12618000233224

Scientific title:

MONARCC: A randomised phase II study of Panitumumab monotherapy and panitumumab plus 5 fluorouracil as first line therapy for RAS and BRAF wild type metastatic colorectal cancer.

Sponsor / Cooperative group:

AGITG

Trial & Patient Characteristics

Cancer TypeBowel and colon
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
SexBoth
Tumour Stream Colorectal cancer
Cancer StageMetastatic or Widespread
Anticipated Start Date2018-03-30
Anticipated End Date2020-01-31

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorPamela Cooper
Emailpamela.cooper@sa.gov.au
Phone08 8222 6140
Principal InvestigatorProfessor Tim Price
Recruitment StatusRecruiting
HospitalFlinders Medical Centre
Clinical Trial CoordinatorAlex Scott-Hoy
Emailalex.scott-hoy@sa.gov.au
Phone08 8204 4830
Principal InvestigatorDr Chris Karapetis
Recruitment StatusRecruiting